Significant Ownership of Logos Global Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Logos Global Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Arsani William - Managing Partner
- Manager location
- San Francisco, CA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Logos Global Management LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Logos Global Management LP
Significant Ownership of Logos Global Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| NERV | Minerva Neurosciences, Inc. | Common Stock | 9.9% | $18,407,093 | 4,435,444 | Logos Global Management LP | 23 Dec 2025 | ||
| PTN | PALATIN TECHNOLOGIES INC | Common Stock | 9.9% | $3,173,262 | +$694,535 | 182,162 | +28% | Logos Global Management LP | 31 Mar 2026 |
| ERAS | Erasca, Inc. | Common Stock | 4.8% | $29,648,000 | -$3,270,000 | 13,600,000 | -9.9% | Logos Global Management LP | 30 Sep 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.8% | $28,035,250 | -$2,207,500 | 3,175,000 | -7.3% | Logos Global Management LP | 30 Sep 2025 |
| OLMA | Olema Pharmaceuticals, Inc. | Common Stock | 4.7% | $16,172,730 | 3,208,875 | Logos Global Management LP | 18 Mar 2025 | ||
| IBIO | iBio, Inc. | Common Stock | 4.6% | $3,810,000 | -$1,270,000 | 1,500,000 | -25% | Logos Global Management LP | 31 Dec 2025 |
| DSGN | Design Therapeutics, Inc. | Common Stock | 4.4% | $16,322,350 | -$4,802,600 | 2,515,000 | -23% | Arsani William | 14 Nov 2025 |
| CBIO | CRESCENT BIOPHARMA, INC. | Ordinary Shares | 4.1% | $7,762,500 | 575,000 | Logos Global Management LP | 30 Jun 2025 | ||
| ARVN | ARVINAS, INC. | Common Stock ("Stock") | 3.4% | $21,300,000 | -$32,376,000 | 2,500,000 | -60% | Logos Global Management LP | 13 Oct 2025 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock | 3.2% | $24,136,750 | +$5,619,900 | 1,675,000 | +30% | Logos Global Management LP | 31 Mar 2026 |
| TENX | Tenax Therapeutics, Inc. | Common Stock | 3% | $11,968,000 | +$2,767,600 | 800,000 | +30% | Logos Global Management LP | 31 Mar 2026 |
| NXTC | NextCure, Inc. | Common Stock | 0% | $0 | 0 | Logos Global Management LP | 31 Dec 2024 | ||
| PRTA | PROTHENA CORP PUBLIC LTD CO | Ordinary Shares | 0% | $0 | -$18,644,000 | 0 | -100% | Logos Global Management LP | 30 Jun 2025 |
| ELEV | Elevation Oncology, Inc. | Common Stock | 0% | $0 | 0 | Logos Global Management LP | 31 Dec 2024 | ||
| ANNX | Annexon, Inc. | Common Stock | 0% | $0 | -$17,028,000 | 0 | -100% | Logos Global Management LP | 30 Jun 2025 |
| IBIO | iBio, Inc. | Common Stock | 0% | 0 | Logos Global Management LP | 31 Mar 2026 |
Schedules 13D/G Reported by Logos Global Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.